Enhancing the dissolution of polymorphs I and II of mefenamic acid by spray drying;Püskürtülerek kurutma ile mefenamik asit'in I ve II polimorflannin disolüsyonunun artırılması

Turkish Journal of Pharmaceutical Sciences

Volumn 9, Issue 1, 2012, Pages 13-26

  Dixit, Mudit ^a   Kini, Ashwini G ^a   Kulkarni, Parthasarthi K ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Crystallinity; Form 1 II; Mefenamic acid; Solubility dissolution; Spray drying

Indexed keywords

2 PROPANOL; DRUG SOLVENT; MEFENAMIC ACID; MICROSPHERE; WATER;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MECHANICS; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TENSILE STRENGTH; X RAY DIFFRACTION;

EID: 84859543230     PISSN: 1304530X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chourasia MK, Vaidya S, Jain N, Jain SK, Utilisation of spherical crystallization for preparation of directly compressible materials, Indian Drugs 41(6), 319-329, 2004.
2. Matsuda Y, Tatsumi E, Physicochemical characterization of furosemide modifications, Int J Pharm 60, 11-26, 1990.
3. Kushida I, Ahizawa K, Solid state characterization of E2101, a novel antispatic drug, J Pharm Sei 91, 2193-2202, 2002.
4. Otsuka M, Matsuda Y, Polymorphism: pharmaceutical aspects, Encyclopedia of Pharm Tech, vol 12, Marcel Dekker, New York, NY, pp 305-326, 1995.
5. Singh D, Marshall PV, Shilds L, York P, Solid-state characterization of chlordiazepoxide polymorphs, J Pharm Sei 87, 655-662, 1998.
6. Ashizawa K, Physico-chemical studies on the molecular details of drug crystals, Pharm Tech Japan 17, 1863-1874, 2001.
7. Aguiar AJ, Zelmer JE, Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid, J Pharm Sei 58, 983-987, 1969.
8. Kokubo H, Morimoto K, Ishida T, Inoue M, Morisaka K, Bioavailability and inhibitory effect for stress ulcer of simetidine polymorphs in rats, Int J Pharm 35, 181-183, 1987.
9. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G, Pharmaceutical solids: a strategic approach to regulatory considerations, Pharm Res, 12, 945-954, 1995.
10. Airaksinen S, Luukkonen P, Jorgensen A, Karjalainen M, Rantanen J, Yliruusi J, Effects of excipients on hydrate formation in wet masses containing theophylline, J Pharm Sei 92, 516-528,2003.
11. Otsuka M, Hasegawa H, Matsuda Y, Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules, Chem Pharm Bull 47, 852-856, 1999.
12. Otsuka M, Ofusa T, Matsuda Y, Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding, Colloids Surf B 13, 263-273, 1999.
13. Summer MP, Enver RP, Carless JE, The influence of crystal form on the radial stress transmission characteristics of pharmaceutical materials, J Pharm Pharmacol 28, 89-99, 1976.
14. Summer MP, Enver RP, Carless JE, Influence of crystal form on tensile strength of compacts of pharmaceutical materials, J Pharm Sei 77, 1172-1175, 1977.
15. Zhang GZ, Gu C, Zeil MT, Burkhardt RT, Munson EJ, Grant DW, Crystallization and transitions of sulfamerazine polymorphs, J Pharm Sei 91, 1089-1100, 2002.
16. Tang XC, Pikal MJ, Taylor LS, The effect of temperature on hydrogen bonding in crystalline and amorphous phase in dihydropyrine calcium channel blockers, Pharm Res 19, 484-490, 2002.
17. Otsuka M, Onoe M, Matsuda Y, Physicochemical stability of Phenobarbital polymorphs at various levels of humidity and temperature, Pharm Res 10, 577-582, 1993.
18. Matsuda Y, Kawaguchi S, Physicochemical characterization of oxyphenbutazone and solid-state stability of its amorphous form under various temperature and humidity conditions, Chem Pharm Bull 34, 1289-1298, 1986.
19. Matsuda Y, Tatsumi E, Physicochemical characterization of furosemide modifications, Int J Pharm 60, 11-26, 1990.
20. Romero S, Escalera B, Bustamante P, Solubility behavior of polymorphs I and II of mefenamic acid in solvent mixtures, Int J Pharm 178, 193-202, 1999.
21. Aguiar AJ, Zelmer JE, Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid, J Pharm Sei 58, 983-987, 1969.
22. Umeda T, Ohnishi N, Yokoyama T, Kuroda T, Kita Y, Kuroda K, Tatsumi E, Matsuda Y, A kinetic study on the isothermal transition of polymorphic forms of tolbutamide and mefenamic acid in the solid state at high temperatures, Chem Pharm Bull 33, 2073-2078, 1985.
23. Killeen MJ, The process of spray drying and spray congealing, Pharm Eng 13, 56-64, 1993.
24. Maa YF, Nguyen PA, Sit K and Hsu CC, Spray drying performance of bench-top spray dryer for protein aerosol powder preparation, Biotech Bioeng 60, 301-309, 1998.
25. Maury M, Murphy K, Kumar S, Shi L and Lee G, Effects of process variables on the powder yield of spray-dried trehalose on a laboratory spray-dryer, Eur J Pharm Biopharm 59,565-573,2005.
26. Adhiyaman R, Basu SK, Crystal Modification of dipyridamole using different solvents and crystallization conditions, Int J Pharm 14, 321(1-2), 27-34, 2006.
27. Panchagnula R, Sundaramurthy P, Pillai O, Agrawal S, Ashok Raj Y, Solid-state characterization of mefenamic acid, J Pharm Sei 4, 1019-1029, 2004.